دورية أكاديمية
أعرض في EDS

Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.

التفاصيل البيبلوغرافية
العنوان: Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
المؤلفون: Andersen S; Department of Cardiology, Aarhus University Hospital, Denmark. Electronic address: stineandersen@clin.au.dk., Axelsen JB; Department of Cardiology, Aarhus University Hospital, Denmark., Ringgaard S; MR Centre, Aarhus University Hospital, Denmark., Nyengaard JR; Core Center for Molecular Morphology, Section for Stereology and Microscopy, Department of Clinical Medicine, Centre for Stochastic Geometry and Advanced Bioimaging, Aarhus University, Denmark., Hyldebrandt JA; Department of Anesthesiology and Intensive Care, Aarhus University Hospital, Denmark., Bogaard HJ; Department of Pulmonology, Amsterdam UMC, the Netherlands., de Man FS; Department of Pulmonology, Amsterdam UMC, the Netherlands., Nielsen-Kudsk JE; Department of Cardiology, Aarhus University Hospital, Denmark., Andersen A; Department of Cardiology, Aarhus University Hospital, Denmark.
المصدر: International journal of cardiology [Int J Cardiol] 2019 Oct 15; Vol. 293, pp. 203-210. Date of Electronic Publication: 2019 Jun 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8200291 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1874-1754 (Electronic) Linking ISSN: 01675273 NLM ISO Abbreviation: Int J Cardiol Subsets: MEDLINE
أسماء مطبوعة: Publication: Amsterdam : Elsevier
Original Publication: Amsterdam : Elsevier/North-Holland Biomedical Press, c1981-
مواضيع طبية MeSH: Heart Ventricles*/drug effects , Heart Ventricles*/physiopathology , Hypertension, Pulmonary*/drug therapy , Hypertension, Pulmonary*/physiopathology , Ventricular Dysfunction, Right*/drug therapy , Ventricular Dysfunction, Right*/physiopathology, Aminobutyrates/*pharmacology , Pulmonary Circulation/*drug effects , Tetrazoles/*pharmacology, Angiotensin II Type 2 Receptor Blockers/pharmacology ; Animals ; Antihypertensive Agents/pharmacology ; Biphenyl Compounds ; Disease Models, Animal ; Drug Combinations ; Hypertrophy, Right Ventricular/drug therapy ; Rats ; Valsartan ; Vascular Remodeling/drug effects
مستخلص: Background: Combined angiotensin II receptor antagonism and neprilysin inhibition by LCZ696 reduces morbidity and mortality in heart failure patients and works by reducing RAAS activity and increasing cGMP levels. This study aims to evaluate the effects of LCZ696 in rats with pulmonary hypertension and right ventricular (RV) failure.
Methods: Pulmonary hypertension was induced in rats (n = 34) by combined exposure to the vascular endothelial growth factor-receptor antagonist SU5416 and hypoxia (SuHx). To distinguish pulmonary vascular from cardiac effects, isolated RV failure was induced by pulmonary trunk banding (PTB) in another group of rats (n = 40). In both models, the development of RV dysfunction was verified before randomization to treatment with LCZ696 (60 mg/kg/day) or vehicle for five weeks.
Results: In the SuHx rats, LCZ696 treatment reduced the increase in RV pressure and the development of RV hypertrophy and RV dilatation compared with vehicle treatment. LCZ696 also reduced wall thickness of the smaller pulmonary arteries. In the PTB rats, LCZ696 treatment did not have any effects on RV hypertrophy or function.
Conclusions: Combined angiotensin II receptor antagonism and neprilysin inhibition reduced RV systolic pressure, hypertrophy, and dilatation in rats with pulmonary hypertension. These effects seem secondary to pulmonary vascular changes, including reduced pulmonary vascular remodeling, as similar effects were not seen in rats with isolated RV failure. LCZ696 may have a therapeutic potential in the treatment of pulmonary hypertension.
(Copyright © 2019 Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: Angiotensin II; Animal models; Natriuretic peptides; Pulmonary hypertension; Right ventricular failure
المشرفين على المادة: 0 (Aminobutyrates)
0 (Angiotensin II Type 2 Receptor Blockers)
0 (Antihypertensive Agents)
0 (Biphenyl Compounds)
0 (Drug Combinations)
0 (Tetrazoles)
80M03YXJ7I (Valsartan)
WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
تواريخ الأحداث: Date Created: 20190717 Date Completed: 20200709 Latest Revision: 20211204
رمز التحديث: 20231215
DOI: 10.1016/j.ijcard.2019.06.065
PMID: 31307846
قاعدة البيانات: MEDLINE
الوصف
تدمد:1874-1754
DOI:10.1016/j.ijcard.2019.06.065